Alzheimer's Clinical Trials in Chicago
View 42 new treatments for Alzheimer's in Chicago, IL, and other areas near me, such as Naperville. Every day, Power helps hundreds of alzheimers patients connect with leading medical research.Donanemab for Alzheimer's Disease
Eli Lilly Clinic, Lombard + 11 more
This trial is testing donanemab, a medication aimed at helping people with Alzheimer's Disease by removing harmful protein clumps from their brains. Donanemab has shown promise in reducing these harmful proteins in Alzheimer's disease.Show More
Verified
AVP-786 for Alzheimer's-related Agitation
Avanir Clinic, Chicago + 1 more
This trial tests a combination of two drugs taken by mouth to help calm severe agitation in people with Alzheimer's disease by balancing brain chemicals.
KarXT for Alzheimer's-Related Psychosis
Karuna Clinic, Berwyn + 2 more
This is a Phase 3 global, multicenter, 52-week, open-label extension (OLE) rollover study for subjects completing study CN012-0026 or CN012-0027. Subjects (randomized or non-randomized) who complete the 38-week CN012-0026 or CN012-0027 study will be eligible to enroll in CN012-0028. The primary objective of the study is to assess the long-term safety and tolerability of KarXT in subjects with psychosis associated with Alzheimer's Disease.Show More
No Placebo Trial
Masupirdine for Agitation in Alzheimer's Disease
Suven Life Sciences Clinic, Chicago + 2 more
This trial will test a medication called masupirdine, which participants will take regularly. It targets people with Alzheimer's disease who are experiencing agitation. The study aims to see if masupirdine can help reduce agitation and ensure it is safe and well-tolerated. Masupirdine has been previously evaluated in patients with moderate Alzheimer's disease and was found to be generally safe and well-tolerated.Show More
KarXT for Alzheimer's-Related Psychosis
Karuna Clinic, Elgin + 1 more
This trial is testing KarXT, a medication for adults aged 55-90 with Alzheimer's Disease and severe psychosis. The goal is to see if KarXT can reduce symptoms like hallucinations and delusions by balancing brain chemicals.Show More
Remternetug for Alzheimer's Disease
Eli Lilly Clinic, Chicago + 4 more
The purpose of this study is to measure the difference in time to developing or worsening memory, thinking, or functional problems due to Alzheimer's disease occurring in participants receiving study drug compared to placebo. Participation could last up to 255 weeks including screening, a double-blind treatment period, and a double-blind observation period. In addition, eligible participants who receive placebo during the double-blind treatment period may choose to extend their study participation to receive open-label remternetug in an extension period.Show More
Donanemab for Early Alzheimer's Disease
Eli Lilly Clinic, Elk Grove Village + 4 more
This trial is testing donanemab, a drug for early Alzheimer's disease. It targets people with early symptoms and specific brain changes. The drug helps remove harmful proteins from the brain, potentially slowing down or improving symptoms.Show More
AR1001 for Alzheimer's Disease
AriBio Clinic, Chicago + 1 more
This trial tests AR1001, a medicine for early Alzheimer's Disease. It focuses on people in the early stages of Alzheimer's, aiming to improve their condition through multiple mechanisms.Show More
Remternetug for Alzheimer's Disease
Eli Lilly Clinic, Chicago + 3 more
This trial tests remternetug, a drug given by injection or IV, in people with early Alzheimer's disease. It aims to find out if the drug is safe and can help improve symptoms or slow down the disease.Show More
Long-Term Safety of Simufilam for Alzheimer's Disease
Cassava Sciences Clinic, Park Ridge + 1 more
The goal of this open-label extension study is to assess long-term safety and tolerability of simufilam 100 mg in subjects who have completed the RETHINK-ALZ or REFOCUS-ALZ Phase 3 clinical trials.Show More
No Placebo Trial
Frequently Asked Questions
How much do alzheimer's clinical trials pay?
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range. Further, most trials will cover the costs of an Uber to-and-from the clinic. Factors that can affect compensation include the phase of the trial, the length of the trial, the frequency of visits, and the specific condition being studied.
Do I need to be insured to participate in a medical study?
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on Cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.
How do alzheimer's clinical trials work?
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll typical be sorted into one of the treatment groups, and will receive your study drug. For some trials, there is a chance you'll receive a placebo. Across alzheimers trials in Chicago, 42% of clinical trials have a placebo. Typically you'll be required to check-in with the clinic every month or two. The average trial length in this city for alzheimers patients is 6 Months.
What does the "phase" of a clinical trial mean?
The phase of a trial reveals what stage the drug is in getting approval for a specific condition. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. Phase 2 trials are those where the drug has some data showing safety in humans, but where effectiveness has typically only been shown in animals and non-human experiments. Phase 1 trials are the trials where we don't have safety data in humans. As a general rule, phase 3 trials are more promising than phase 2, and phase 2 trials are more promising than phase 1.
Where in Chicago is research being conducted for alzheimer's?
Prominent hospitals in Chicago conducting Alzheimer's clinical trials include Rush University Medical Center and Northwestern University. As of the latest data, there are approximately 15 trials ongoing, with activity also noted in the Andersonville neighborhood on the north side.
What promising new drugs are being tested?
In Chicago, Alzheimer's research is focusing on treatments like Monoclonal Antibodies and Radiopharmaceuticals. Notable drugs being studied include Donanemab, Amyvid, and Lecanemab.